reason report
busi solid pharmedium still weigh
bottom line follow earn post
decent result guidanc exclud pharmedium lash
impact reduc ep estim account
pharmedium increas long-term estim due
mainli slightli favor gross margin assumpt
core distribut busi perform well quarter
manag highlight major gross profit growth
driven segment larg off-set
headwind pharmedium addit encourag
gener deflat brand inflat appear stabl
gener complianc rate improv continu like
smith acquisit view posit specialti
signific posit relationship mp also
signific posit store on-board
end quarter maintain pt
core busi continu perform well mostli offset
pharmedium headwind manag disclos
pharmedium ship volum less half prior year
quarter due headwind memphi facil well hepat
 creat revenu headwind howev growth core
busi abl larg off-set challeng deliv y/
gross profit growth specialti distribut busi
continu deliv good revenu growth y/i
consecut quarter growth exceed volum also
strong sever quarter driven oncolog ophthalmolog ms
therapeut quarter complet on-board
store though half pharmaci servic
entir quarter on-board process complet ahead
schedul manag expect achiev full quarter impact
addit store
stabil brand gener trend bode well pharma
suppli chain continu strength core pharma busi
manag continu expect gener deflat rang
brand drug price inflat rang
call manag describ gener deflat
headwind busi continu stabil brand
gener inflat rate along progress contract re-balanc
effort custom led competit stabil across
industri encourag manag commentari surround
stabl price trend bode well group
net debt total capit
ep
estimate lt ep growth base
compani inform leerink partner llc research
revenu present billion dollar
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
pharmedium impact last longer initi expect
manag initi guid impact pharmedium
expect temporari howev memphi facil remain
off-lin sinc decemb albeit voluntarili manag expect
memphi facil fulli oper
continu expect facil back on-line phase approach
manag guid contribut pharmedium
essenti remov financi expect
three facil recent complet fda inspect
on-line far year-to-d spent remedi cost
pharmedium expect incur cost call
manag clarifi remedi cost includ
adjust result manag describ busi high-
margin strong manag view indic
good rebound also explain believ
lost custom competit sound optimist
abl win back busi lost
lash continu present headwind manag believ
right path segment continu face
headwind lash consult busi despit continu
challeng manag continu believ right
path disclos sever new busi win new program
quarter success on-board sever new client continu
like posit specialti agre manag
lash well posit on-going shift specialti medic
administ altern site includ patient home
outlook guid lower end previou rang due
pharmedium lash headwind prior guidanc larg
reiter quarter manag expect result come
toward bottom end rang pharmedium headwind
expect larg off-set improv volum margin
pharma segment incom contribut pharmedium
essenti remov guidanc continu soft lash led
manag guid adj oper incom segment
y/i overal adj oper incom guidanc
expect flat y/i last quarter guidanc growth
total oper expens enterpris expect
increas y/i previou rang
tweak estim reduc ep account
pharmedium lash though increas
ep estim due mainli better gross margin assumpt
memphi facil pharmedium come back on-line would expect
earn busi ramp back memphi facil like
back on-line fy phase manner face
headwind core busi view perform well
maintain op rate pt
one pharmaceut distributor estim compani
captur pharmaceut distribut market term revenu
primari differenti distributor compani
focu specialti drug firm relationship estim
compani revenu deriv amerisourcebergen specialti group half
total revenu come oncology-rel busi come
drug compani non-specialti drug servic believ compani concentr
oncology-rel drug posit mani larg pend launch market
compani seem intens focu keep cost lean drive oper
margin expans watch measur everi basi point oper margin expans
quarterwhich view posit furthermor manag tend return signific
portion compani free cash flow back sharehold via common stock repurchas
dividend final abc relationship walgreen signific posit view sinc
walgreen own portion sinc walgreen use primari
distributor stand benefit wba growth market includ increment
volum result wba/ transact well increment volum
narrow network deal recent ink includ deal esrx/tricar optum
prime envis headwind exist includ competit sell-sid environ
on-going risk brand gener inflat rate presid trump potenti polici around
brand price unclear though believ ultim work industri despit
risk believ concern current reflect share price
increment revenu off-set mani headwind view given abc grow
market share seemingli decent brand inflat rate purchas power wbad growth
specialti market rate share outperform
share trade ep estim behind
ntm price-to-earnings histor averag rel ep trade
trade view deserv premium
group mainli abc relationship transact believ new
client win posit renew comp eas higher oper cost allevi
trend gener deflat stabil next month expect
share trade ep would put stock
estim includ guid benefit tax reform worth annual
competit intens amerisourcebergen compet two larg drug
distributor competit among intens
could lead either posit neg earn revis furthermor chain
independ consolid usual one distributor retain contract
exampl walgreen acquisit duan read acquisit long
unfavor impact result larg billion dollar piec
busi often chang hand occurr happen past
may happen futur competit could also lead price eros medco
health solut part esrx repres revenu pre-wag
top ten custom repres revenu pre-wag custom
lost could materi advers impact earn share price
custom face financi hardship abil collect
receiv could becom challeng insolv supplier could also result
advers impact financi result stock price
price economi impact earn result
brand-nam manufactur buy-sid contract fee-for-servic ff
arrang inflat deflat brand-nam drug usual less
impact earn rel contract ff howev sinc price receiv
custom often inflation-bas compon earn could unfavor
impact addit economi weak fewer peopl actual buy prescript
drug due concern discretionari spend lack health insur
compani margin could come pressur
govern regul could advers impact compani
pharmaceut drug distribut industri highli regul state feder
agenc includ fda variou state board law
pass may pass futur intent increas safeti
may like result higher cost exampl radio frequenc
identif devic may prove costli track trace chain custodi
technolog also requir hold valid state-level
licens meet variou secur oper standard failur compli
feder state local law could advers impact compani earn
chang reimburs rate could impact earn effect januari
deficit reduct act dra chang feder upper limit
lowest publish price gener averag manufactur
price health reform set less
medicaid improv patient provid act mippa delay
adopt make public least delay implement set
becom public reimburs compani
retail custom come pressur could advers impact firm
sell-sid margin addit reimburs rate chang awp
awp roll back could unfavor impact
earn declin asp reimburs medicar certain specialti drug
could also advers impact result compani revenu growth
rate certain drug use oncolog come pressur
expand warn product safeti label nation coverag decis
could advers impact compani revenu growth rate reform
drug reimburs chang canada could also advers impact
chang due health reform could advers impact compani product
servic highli complex pervas throughout entir healthcar
system extens array reimburs mechan player within
industri includ manag care medicar medicaid pbm supplier
materi chang entiti health reform could impact
margin consolid competitor supplier custom
purchas group could advers impact compani earn
litig alway risk compani subject signific number healthcar
law includ fals claim act whistl blower act law relat sale
purchas pharmaceut product exampl offer remuner provid
use certain drug may illeg case
oper risk compani make acquisit risk integr
could caus cost rise oper issu occur addit compani
embark cost save program well streamlin process could
result oper issu data lost compani new
implement program face challeng could advers impact
compani earn share price implement compani enterpris
resourc plan erp system could also advers impact earn
incom statement model fiscal year end septemb mm
good sold
distribut sell administr
total revenu
total revenu
impair intang
amort intang
total revenu
total revenu
weight average number share
employe sever litig
